Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease
Haixia Su, Sheng Yao, Wenfeng Zhao, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 162

Showing 26-50 of 162 citing articles:

Structural Basis for Coronaviral Main Proteases Inhibition by the 3CLpro Inhibitor GC376
Cheng‐Wen Lin, Zhu Zhi-min, Haihai Jiang, et al.
Journal of Molecular Biology (2024) Vol. 436, Iss. 6, pp. 168474-168474
Closed Access | Times Cited: 8
Pyrogallol protects against influenza A virus‐triggered lethal lung injury by activating the Nrf2–PPAR‐γ–HO‐1 signaling axis
Beixian Zhou, Linxin Wang, Sushan Yang, et al.
MedComm (2024) Vol. 5, Iss. 4
Open Access | Times Cited: 8
Scutellarin activates IDH1 to exert antitumor effects in hepatocellular carcinoma progression
Zhao Cui, Caifeng Li, Wei Liu, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 4
Open Access | Times Cited: 7
Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review
Ya-Qi Xiao, Jiao Long, Shuang‐Shuang Zhang, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107380-107380
Closed Access | Times Cited: 7
Identification of two flavonoids antiviral inhibitors targeting 3C-like protease of porcine epidemic diarrhea virus
Zhonghua Li, Liangyun Zhu, Lu Wang, et al.
Frontiers in Microbiology (2024) Vol. 15
Open Access | Times Cited: 6
Kinetic comparison of all eleven viral polyprotein cleavage site processing events by SARS-CoV-2 Main Protease using a linked protein FRET platform
Calem Kenward, M. Vuckovic, Mark Paetzel, et al.
Journal of Biological Chemistry (2024) Vol. 300, Iss. 6, pp. 107367-107367
Open Access | Times Cited: 6
Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery
Zhonglei Wang, Liyan Yang, Xian‐En Zhao
Computational and Structural Biotechnology Journal (2021) Vol. 19, pp. 4684-4701
Open Access | Times Cited: 36
Lead/Drug Discovery from Natural Resources
Zhihong Xu, Barrett E. Eichler, Eytan A. Klausner, et al.
Molecules (2022) Vol. 27, Iss. 23, pp. 8280-8280
Open Access | Times Cited: 28
Improved SARS-CoV-2 main protease high-throughput screening assay using a 5-carboxyfluorescein substrate
Scott Legare, Fabian Heide, Ben A. Bailey-Elkin, et al.
Journal of Biological Chemistry (2022) Vol. 298, Iss. 4, pp. 101739-101739
Open Access | Times Cited: 25
Oridonin Inhibits SARS‐CoV‐2 by Targeting Its 3C‐Like Protease
Baisen Zhong, Weiyu Peng, Shan Du, et al.
Small Science (2022) Vol. 2, Iss. 6
Open Access | Times Cited: 25
Exploring new catechin derivatives as SARS-CoV-2 Mpro inhibitors from tea by molecular networking, surface plasma resonance, enzyme inhibition, induced fit docking, and metadynamics simulations
Zi Yang, Wei Wang, Yan Qi, et al.
Computers in Biology and Medicine (2022) Vol. 151, pp. 106288-106288
Open Access | Times Cited: 23
AI-Accelerated Design of Targeted Covalent Inhibitors for SARS-CoV-2
Rajendra P. Joshi, Katherine Schultz, Jesse Wilson, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 5, pp. 1438-1453
Open Access | Times Cited: 14
Sulforaphane is a reversible covalent inhibitor of 3‐chymotrypsin‐like protease of SARS‐CoV‐2
Zinuo Chen, Ruikun Du, Laura Cooper, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 3
Closed Access | Times Cited: 14
Aurones: A Promising Scaffold to Inhibit SARS-CoV-2 Replication
Guilherme S. Caleffi, Alice dos Santos Rosa, Luana G. de Souza, et al.
Journal of Natural Products (2023) Vol. 86, Iss. 6, pp. 1536-1549
Closed Access | Times Cited: 14
Recent Advances on SARS-CoV-2 Mpro Inhibitors: From Nirmatrelvir to Future Perspectives
Andrea Citarella, Alessandro Dimasi, Davide Moi, et al.
(2023)
Open Access | Times Cited: 14
Anti-SARS-CoV-2, antioxidant and immunomodulatory potential of dietary flavonol quercetin: Focus on molecular targets and clinical efficacy
Biswanath Dinda, Manikarna Dinda, Subhajit Dinda, et al.
European Journal of Medicinal Chemistry Reports (2023) Vol. 10, pp. 100125-100125
Open Access | Times Cited: 14
Discovery and Mechanism Study of SARS-CoV-2 3C-like Protease Inhibitors with a New Reactive Group
Pengxuan Ren, Hui Li, Tianqing Nie, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 12266-12283
Closed Access | Times Cited: 13
Inhibitory Activity of Flavonoid Scaffolds on SARS-CoV-2 3CLpro: Insights from the Computational and Experimental Investigations
Nopawit Khamto, Kraikrit Utama, Panida Boontawee, et al.
Journal of Chemical Information and Modeling (2024) Vol. 64, Iss. 3, pp. 874-891
Closed Access | Times Cited: 5
Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CLpro Inhibitors as anti-SARS-CoV-2 Drug Candidate
Zhidong Jiang, Bo Feng, Lu Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 15, pp. 12760-12783
Closed Access | Times Cited: 5
Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions
Ahmed M. Shawky, Faisal A. Almalki, Hayat Ali Alzahrani, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116704-116704
Closed Access | Times Cited: 5
Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLpro inhibitors for treating COVID-19
Jianwei Zhang, Yuan Xiong, Feng Wang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 228, pp. 114030-114030
Open Access | Times Cited: 32
In silicoscreening and covalent binding of phytochemicals ofOcimum sanctumagainst SARS-CoV-2 (COVID 19) main protease
Pranab Kishor Mohapatra, Kumar Sambhav Chopdar, Ganesh Chandra Dash, et al.
Journal of Biomolecular Structure and Dynamics (2021) Vol. 41, Iss. 2, pp. 435-444
Closed Access | Times Cited: 28
Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery
Kirsten McAulay, Alan Bilsland, Marta Bon
Pharmaceuticals (2022) Vol. 15, Iss. 11, pp. 1366-1366
Open Access | Times Cited: 22
Potential of green tea EGCG in neutralizing SARS-CoV-2 Omicron variant with greater tropism toward the upper respiratory tract
Zhichao Zhang, Meng Hao, Xiangchun Zhang, et al.
Trends in Food Science & Technology (2022) Vol. 132, pp. 40-53
Open Access | Times Cited: 22
In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease
Muya Xiong, Tianqing Nie, Qiang Shao, et al.
European Journal of Medicinal Chemistry (2022) Vol. 231, pp. 114130-114130
Open Access | Times Cited: 21

Scroll to top